切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2011, Vol. 05 ›› Issue (01) : 62 -67. doi: 10.3877/cma.j.issn.1674-0793.2011.01.019

所属专题: 文献

循证医学

无法手术切除的肝细胞癌TACE与RFA治疗的Meta分析
范文哲1, 李家平1,(), 杨建勇1, 王于1, 向贤宏1, 李鹤平1   
  1. 1. 510080 广州,中山大学附属第一医院放射介入科
  • 收稿日期:2010-08-29 出版日期:2011-02-01
  • 通信作者: 李家平
  • 基金资助:
    广东省自然科学基金(07001663); 广东省科技计划(2009B030801027)

Interventional treatmeant for unresectable hepatocellular carcinoma: a systematic review and Meta-analysis

Wen-zhe FAN1, Jia-ping LI1,(), Jian-yong YANG1, Yu WANG1, Xian-hong XIANG1, He-ping LI1   

  1. 1. Department of Interventional Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
  • Received:2010-08-29 Published:2011-02-01
  • Corresponding author: Jia-ping LI
  • About author:
    Corresponding author: LI Jia-ping, Email:
引用本文:

范文哲, 李家平, 杨建勇, 王于, 向贤宏, 李鹤平. 无法手术切除的肝细胞癌TACE与RFA治疗的Meta分析[J/OL]. 中华普通外科学文献(电子版), 2011, 05(01): 62-67.

Wen-zhe FAN, Jia-ping LI, Jian-yong YANG, Yu WANG, Xian-hong XIANG, He-ping LI. Interventional treatmeant for unresectable hepatocellular carcinoma: a systematic review and Meta-analysis[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(01): 62-67.

目的

比较经动脉灌注化疗栓塞(TACE)联合射频消融(RFA)与单独TACE或RFA治疗无法手术切除肝细胞癌(UHCC)的临床疗效。

方法

收集国内外关于TACE+RFA与单独TACE或RFA治疗UHCC的随机、对照临床研究文献(RCT),采用RevMan 4.2软件,对符合纳入标准的8个独立性研究进行Meta分析,分析的主要对象为生存期及肿瘤完全坏死率。

结果

TACE+RFA较单独TACE提高患者1年、2年及3年生存率(均P<0.01),较单独RFA提高1年及2年生存率(P=0.03、P<0.01),而3年生存率则缺乏统计学差异(P=0.16);而对于肿瘤完全坏死率,联合治疗明显较低(均P<0.01)。

结论

TACE联合RFA治疗UHCC的疗效较单独TACE或单独RFA治疗好,而远期疗效较单独TACE能有效提高患者生存率,较单独RFA能提高1年及2年生存率。

Objective

To compare the therapeutic effects of transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation(RFA) to TACE or RFA alone for unresectable hepatocellular carcinoma (UHCC).

Methods

All data of patients with UHCC underwent TACE+RFA versus TACE or RFA in randomized-controlled clinical trials (RCT) were collected from literature by electronic searching. Meta-analysis that recommended was done for the data of 8 researches enrolled in criteria by using RevMan 4.2 software in this study. Objects were survival and rate of complete tumor necrosis.

Results

TACE+RFA group had a statistically higher rate in 1-, 2-, 3-year survival compared with that of TACE group (all P<0.01). It also had a higher rate in 1-, 2-year survival than RFA group (P=0.03, P<0.01), but not in 3-year survival (P=0.16). As to the rate of complete tumor necrosis, combined therapy was better than either monotherapy (both P<0.01).

Conclusions

The local efficacy of TACE plus RFA for UHCC is better than either monotherapy. As to the prospective efficacy combined therapy can elevate the patients’ survival rate compared with that of TACE alone and prolong patients’ 1-, 2-year survival time compared with that of RFA alone. But there is no statistic different in 3-year patients’ survival rate when TACE plus RFA compared to RFA alone.

表1 入组RCT的基本情况
图1 TACA+RFA与单独TACE治疗UHCC患者1年、2年、3年生存率的Meta分析结果
图2 TACA+RFA与单独RFA治疗UHCC患者1年、2年、3年生存率的Meta分析结果
图3 TACA+RFA与单独TACE治疗UHCC肿瘤完全坏死率的Meta分析结果
图4 TACA+RFA与单独RFA治疗UHCC肿瘤完全坏死率的Meta分析结果
1
Parkin DM, Bray F, Ferlay P. Global cancer statistics, 2002. CA cancer J Clin, 2005, 55: 74-108.
2
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 2003, 37(2): 429-442.
3
Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma. Cancer, 2009, 115(9): 1914-1923.
4
Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005, 129(1): 122-130.
5
Gasparini D, Sponza M, Marzio A, et al. Combined treatment TACE and RF ablation, in HCC: preliminary results. Radiol Med, 2002, 104(5-6): 412-420.
6
Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable nonearly hepatocellular carcinoma (HCC). Eur Radiol 2006, 16(3): 661-669.
7
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials, 1996, 17(1): 12-20.
8
Wang YB, Chen MH, Yan K, et al. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res, 2007, 16(3): 389-397.
9
姬统理, 杜锡林, 李刚, 等. 肝动脉化疗栓塞术加经皮肝穿刺射频消融术治疗.原发性肝癌56例. 现代肿瘤医学, 2004, 12(6): 540-541.
10
靳殿功, 孔棣, 王桐, 等. 射频消融联合经导管肝动脉栓塞化疗序贯性治疗原发性肝癌. 中国中西医结合外科杂志, 2009, 15(2): 141-143.
11
Shibata T, Isoda H, Hirokawa Y, et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology, 2009, 252(2): 905-913.
12
李增才, 黄声稀, 陆雷, 等. TACE联合RFA治疗中晚期原发性肝癌的疗效观察. 临床肿瘤学杂志, 2008, 13(2): 147-149.
13
Yang P, Liang M, Zhang Y, et al. Clinical application of a combination therapy of Lentinan, multi-electrode RFA and TACE in HCC. Adv Ther, 2008, 25(8): 787-794.
14
康春博, 许洪斌, 王世龙, 等. TACE联合RFA治疗大肝癌的研究. 中华肝胆外科杂志, 2007, (12): 137-140.
15
唐树尧, 解亦斌, 姜涛, 等. 原发性肝癌的疗效分析. 哈尔滨医科大学报, 2005, 39(2): 183-187.
16
Kirikoshi H, Saito S, Yoneda M, et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy of hepatocellular carcinoma. Hepatol Res, 2009, 39(6): 553-562.
17
Takahashi S, Kudo M, Chung H, et al. Initial treatment response is essential to improve survivals in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology, 2007, 72(suppl 1): 98-103.
18
Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int, 2010, 30(5): 741-749.
19
Cui Y, Zhou L Y, Ji M, et al. Percutaneous radiofrequency ablation therapy for hepatic malignancies in 114 patients. Chin J Mod Med (Chinese), 2004, 14(20): 129-131, 135.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 马旦杰, 黄品同, 徐琛, 周芳芳, 潘敏强. 超声造影LI-RADS系统联合甲胎蛋白对有无高危因素背景人群肝细胞癌的诊断价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(03): 288-296.
[3] 丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J/OL]. 中华医学超声杂志(电子版), 2023, 20(09): 930-938.
[4] 李淼, 朱连华, 韩鹏, 姜波, 费翔. 高帧频超声造影评价肝细胞癌血管形态与风险因素的研究[J/OL]. 中华医学超声杂志(电子版), 2023, 20(09): 911-915.
[5] 李敏, 杨世英, 高晓琴, 周丹, 唐筱, 张立婷. 维生素A与慢性肝病相关性研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 65-70.
[6] 赵向阳, 刘双池, 张懿刚, 陶滔, 谈燚. 顺铂对肝细胞癌Hep3B细胞程序性死亡配体1表达及药物敏感性的研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 51-55.
[7] 胡森焱, 徐冬, 方健, 谢冬冬, 王财庆. ICG荧光显影Laennec膜入路腹腔镜解剖性肝切除的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 513-516.
[8] 陈政, 叶庆旺, 赵东波, 石鑫, 吴建强, 余德才. 定位针引导下腹腔镜精准局部肝切除应用探索[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(02): 125-128.
[9] 宋燕京, 乔江春, 宋京海. 中晚期肝癌TACE联合免疫靶向转化治疗后右半肝切除术一例[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 227-230.
[10] 莫鹏, 郭杏春, 梁秀娟, 王耀明. 超声引导与CT引导射频消融治疗肝细胞癌患者疗效及预后比较[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 151-154.
[11] 万菲, 任勇军. 原发性肝细胞癌肿瘤标志物研究进展[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(01): 77-81.
[12] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[13] 陆知非, 华永飞, 姜哲康, 高过, 江寅, 王高卿. 初始不可切除肝癌转化治疗的影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 268-274.
[14] 倪管崟, 缪小赟, 丁家安, 田鹏程, 倪才方. 锥形束计算机断层扫描在肝癌介入诊疗中的应用进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(03): 256-260.
[15] 崔皓然, 顾俊鹏, 任伟新. 基于经导管动脉化疗栓塞联合治疗肝癌伴门静脉癌栓的进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(01): 64-69.
阅读次数
全文


摘要